ALK B ALK-ABELLO A/S

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff as set forth in the attached announcement.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

Attachment



EN
27/08/2024

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier ...

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): I henhold til artikel 19 i EU-forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende medarbejderes transaktioner: Bestyrelsen har tidligere tildelt aktieoptioner og performance-aktier i ALK-Abelló A/S, jf. selskabs­meddelelse nr. 08/2023 af 31. marts 2023. Retten til aktieoptioner og performance-aktier kunne opnås i april 2026, under forudsætning af, at ALK opnår de forud aftalte...

April 8, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Report on transactions with ALK-Abelló A/S B shares and associated sec...

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff: The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 08/2023 of 31 March 2023. The right to share options and performance shares may be achieved in April 2026, provided that ALK achi...

April 8, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til dir...

Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere ALK (ALKB:DC / Nasdaq Copenhagen: ALK B):  I henhold til selskabets vederlagspolitik, som er vedtaget på selskabets ordinære generalforsamling den 16. marts 2026, og i tråd med selskabets sædvanlige praksis har bestyrelsen truffet beslutning om at tildele indtil i alt 145.000 aktiebaserede instrumenter i overensstemmelse med selskabets langsigtede incitamentsprogram (LTIP) for direktion og en kreds af ledende medarbejdere for 2026. Formålet med LTIP er at tilskynde og belønne langsigtet vær...

April 1, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Grant of share-based long-term incentive instruments to members of the...

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 16 March 2026 and in line with the company’s usual practice, the Board of Directors has passed a resolution to grant up to a total of 145,000 share-based instruments for the purpose of the company’s long-term incentive plan (LTIP) for the Board of Management and key employees for 2026. The objectives of the LTIP are to incentivise and reward lon...

April 1, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

EURneffy 1 mg approved across the EU as the first and only needle-free...

EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European Commission (EC) granted marketing authorisation for EURneffy® 1 mg – extending a class of treatment previously available only by injection. EURneffy® 1 mg is now indicated for the emergency treatment of anaphylaxis due to insect stings or bites, foods, me...

March 31, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch